Re: What About The Requested Increase of 150 M MNKD Shares in Share Authorization?
Ideally, any new large acquiring shareholder of the shares referenced above would not have a competing insulin or diabetic "helping" product. Rather, it would merely see the potential ROI involved here, and take the risk of investing its funds for capital gains. Let MNKD hire its personnel and build its infrastructure with the funds received, and let MNKD market the Afrezza product as it sees fit, without any competitive product constraints. If the share acquirer happened to be a large pharmaceutical company, it could also lend support on the regulatory development front, both domestically and internationally. JMHO.